The trials are being conducted in cooperation with Mahidol University’s Faculty of Tropical Medicine by delivering shots to 18 volunteers on Monday.
The home-grown vaccine candidate is being developed by the GPO, with Mahidol University’s Tropical Medicine Department and an American non-profit organization and uses an inactivated virus to trigger immunity.
Mahidol University acting President Prof. Bangjong Mahaisavariya said 460 volunteers would be accepted for the human trials, 210 of whom would be used in the first phase. Phase two is expected to begin in July, with results by year-end.
23 Mar 2021